BioBoss is a podcast about leadership in the biopharma community. Hear directly from the founders and CEOs of today's most innovative companies. Listen in as Wyant Simboli Principal and branding veteran John Simboli poses the questions "What drives you? How do you create change? Why should people care?" to biopharma leaders and hear insights on this rapidly developing field.
#54 - Luca Benatti: CEO, EryDel
Luca Benatti, CEO of EryDel, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how EryDel is working to develop specialized therapies for the treatment of rare diseases by using the patient’s own blood.
#53 - Elisabet de los Pinos: Founder/CEO, Aura Biosciences
Elisabet de los Pinos, founder and CEO of Aura Biosciences, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how Aura is working to envision new ways to treat cancer.
#52 - Paul Radspinner: Founder & CEO, Flugen
Paul Radspinner, founder and CEO of Flugen, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Flugen is working to develop a more effective vaccine in the fight against influenza and respiratory disease.
#51 - Jesús Martin-Garcia: CEO of GeNeuro
Jesús Martin-Garcia, CEO of GeNeuro, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Geneuro is working to develop treatments against neurological disorders and autoimmune diseases by neutralizing causal factors encoded by Human Endogenous Retroviruses.
#50 - Cliff Stocks: Founder and CEO, OncoResponse
Cliff Stocks, founder and CEO of OncoResponse speaks with BioBoss host John Simboli. Hear Cliff’s insights about leadership in biopharma and how OncoResponse is working to identify fully human monoclonal antibodies as therapeutics for the treatment of cancer.
#49 - Brian Finrow: Co-founder & CEO, Lumen Bioscience
Brian Finrow, Co-founder and CEO of Lumen Bioscience, speaks with BioBoss host and biopharma branding veteran John Simboli. Hear Brian’s thoughts about leadership and how Lumen Biosciences is working to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology.